Developer docs
API playgroundTry for free, no card

Search company profiles

Affinia Therapeutics

Full company profile

uuid00004dv

Namestring
Affinia Therapeutics
Legal namestring
Affinia Therapeutics, Inc.
Websiteurl
affiniatx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Affinia Therapeutics is a clinical-stage biotechnology company founded in 2021 and headquartered in Waltham, Massachusetts, that develops rationally designed adeno-associated virus (AAV) gene therapies for rare and prevalent genetic diseases. Its lead program, AFTX-201, is an investigational gene therapy delivering a full-length human BAG3 transgene via the proprietary ATC-187 capsid for the treatment of BAG3-associated dilated cardiomyopathy (BAG3 DCM), a genetic heart condition affecting more than 70,000 patients across the U.S., Canada, the EU, and the UK. The company is currently enrolling the UPBEAT Phase 1/2 multicenter clinical trial at sites in the U.S. and Canada, and has secured FDA IND acceptance, FDA Fast Track designation, EMA Orphan Drug designation, and Health Canada CTA approval for the program.

The company's core technology is the ART (Affinia Rationally-designed Therapies) platform, which combines AI, structural modeling, and next-generation sequencing to engineer novel AAV capsids, therapeutic payloads, and manufacturing processes. Two proprietary capsids anchor the platform: ATC-187, which delivers a fully human BAG3 transgene to cardiac tissue at 5-10-fold lower doses than conventional AAV9 or AAVrh74 capsids with homogeneous distribution across heart cells, and ATC-134, a blood-brain barrier penetrant capsid demonstrating greater than 90% neuron transduction in non-human primates. Affinia has also developed a proprietary high-yield manufacturing process achieving harvest titers above 6e15 vg/L, supporting potential commercial supply at 50-250L scale.

Affinia is a privately held, venture-backed company with no commercial revenue. It has raised approximately $210 million across a $60 million Series A (2020), $110 million Series B (2021, co-led by EcoR1 Capital and Farallon Capital), and $40 million Series C (October 2025, led by New Enterprise Associates with Eli Lilly & Company participation). The business model is clinical-stage gene therapy development oriented toward one-time treatment revenue; the lead asset is investigational and supplied at no cost to trial participants. Investors on the board include Atlas Venture, NEA, F-Prime Capital, and others, and management includes multiple former AveXis executives involved in the development and launch of Zolgensma.

Short descriptiontext

Affinia Therapeutics is a clinical-stage biotech developing rationally designed AAV gene therapies for rare diseases, with lead program AFTX-201 in Phase 1/2 trials for BAG3-associated dilated cardiomyopathy and a broader platform spanning cardiac and CNS indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, gene therapy development, cardiac gene therapy, biologics manufacturing, rare disease therapeutics
Industry3 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Scientific Research and Development Services5417
Product category
Gene Therapy / AAV Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene Therapy Development
TypeOne Time License
Description

Affinia Therapeutics is a clinical-stage biotech company developing gene therapies. No commercial revenue yet as the lead program AFTX-201 is in Phase 1/2 clinical trials. The company is funded through venture capital financing.

pharmaceutical-technology.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Affinia Therapeutics develops rationally designed AAV gene therapies targeting rare and prevalent diseases of the heart and central nervous system, with lead candidate AFTX-201 delivering a fully human BAG3 transgene via the proprietary ATC-187 capsid for BAG3-associated dilated cardiomyopathy. The company's ART platform combines AI, structural modeling, and next-generation sequencing to engineer novel capsids, payloads, and manufacturing processes that achieve superior tissue targeting at 5-10-fold lower doses than conventional AAV gene therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Doses 5-10-fold lower than conventional AAV gene therapies
+4 more records
Product overview1 text field

Affinia Therapeutics is a clinical-stage biotech company developing a pipeline of first-in-class and best-in-class AAV gene therapies. The core offering includes AFTX-201, an investigational gene therapy for BAG3-associated dilated cardiomyopathy, which uses the proprietary ATC-187 capsid delivered via a one-time IV infusion. The company operates the ART (Affinia Rationally-designed Therapies) platform that employs AI and structural modeling to rationally design novel capsids (ATC-187 for cardiac, ATC-134 for CNS), payloads, and manufacturing processes. The platform enables lower dosing (5-10-fold) than conventional AAV gene therapies while achieving superior tissue transduction. Pipeline also includes programs for CNS diseases using BBB-penetrant capsids and collaborations for Myotonic Dystrophy Type 1.

Product and service1 record
1AFTX-201
CategoryGene Therapy Product Candidate
Description

Investigational AAV gene therapy delivering a fully human, full-length BAG3 transgene via the proprietary ATC-187 capsid, designed to address the underlying genetic cause of BAG3-associated dilated cardiomyopathy. Engineered for efficient cardiac transduction at doses 5-10-fold lower than conventional AAV gene therapies, administered as a one-time IV infusion.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeOthersAnnounced on2026-01-01
Description

First planned clinical trial site for the UPBEAT clinical trial investigating AFTX-201 in BAG3 DCM patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Forge Biologics serves as the GMP manufacturing partner for AFTX-201 production. The manufacturing process was successfully developed by Affinia and transferred to Forge for clinical supply manufacturing.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Joint collaboration pairing Affinia's myotropic capsid ATC-187 with Modalis' epigenetic editing payload for development of a potential best-in-class gene therapy for Myotonic Dystrophy Type 1 (DM1).

Strategic tierMinorTypeOthers
Description

Canadian research institution with Dr. Rafik Tadros involved as a key opinion leader in BAG3 DCM research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage gene therapy company focused on cardiac diseases, including AAV-based therapies for genetic cardiomyopathies. Directly comparable as a cardiac-focused AAV gene therapy developer in similar stage and indication space as Affinia.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV and lentiviral therapies for rare diseases, including cardiac and CNS indications. Comparable as a multi-platform rare disease gene therapy developer at similar clinical stage.

TypeDirect peer
Description

Genetic medicines company developing AAV gene therapies and other modalities for cardiomyopathies and heart failure. Directly comparable as a cardiac-focused genetic medicine developer with gene therapy programs.

TypeBroad incumbent
Description

Established AAV gene therapy platform company with approved therapy (ABECMA collab) and broad pipeline across ophthalmology, CNS, and metabolic diseases. Larger incumbent with comparable AAV platform technology and broader indication scope.

TypeBroad incumbent
Description

Large rare disease biotech that developed and launched Roctavian, an AAV5 gene therapy for hemophilia A. Comparable as an established player commercializing AAV gene therapy for rare genetic diseases.

TypeDirect peer
Description

Commercial-stage gene therapy company with approved AAV-based therapy (VYJUVEK) for rare dermatological disease. Comparable as a clinical-to-commercial AAV gene therapy developer focused on rare monogenic diseases.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company developing treatments for hemophilia, Huntington's disease, and other rare diseases. Comparable as an established AAV gene therapy developer at similar clinical stage.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for CNS and rare diseases, led by former AveXis CEO Sean Nolan (now Affinia's Chairman). Comparable leadership pedigree and AAV gene therapy focus.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other rare neuromuscular diseases. Comparable as an AAV gene therapy developer for rare genetic diseases.

TypeBroad incumbent
Description

Large pharmaceutical company that acquired AveXis for $8.7B and commercializes Zolgensma, the first systemic AAV gene therapy. Comparable as the established leader in AAV gene therapy commercialization and Affinia's lineage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Affinia Therapeutics

Gene Therapy / AAV Therapeuticsaffiniatx.com

Affinia Therapeutics is a clinical-stage biotech developing rationally designed AAV gene therapies for rare diseases, with lead program AFTX-201 in Phase 1/2 trials for BAG3-associated dilated cardiomyopathy and a broader platform spanning cardiac and CNS indications.

What Affinia Therapeutics does

Affinia Therapeutics is a clinical-stage biotechnology company founded in 2021 and headquartered in Waltham, Massachusetts, that develops rationally designed adeno-associated virus (AAV) gene therapies for rare and prevalent genetic diseases. Its lead program, AFTX-201, is an investigational gene therapy delivering a full-length human BAG3 transgene via the proprietary ATC-187 capsid for the treatment of BAG3-associated dilated cardiomyopathy (BAG3 DCM), a genetic heart condition affecting more than 70,000 patients across the U.S., Canada, the EU, and the UK. The company is currently enrolling the UPBEAT Phase 1/2 multicenter clinical trial at sites in the U.S. and Canada, and has secured FDA IND acceptance, FDA Fast Track designation, EMA Orphan Drug designation, and Health Canada CTA approval for the program.

The company's core technology is the ART (Affinia Rationally-designed Therapies) platform, which combines AI, structural modeling, and next-generation sequencing to engineer novel AAV capsids, therapeutic payloads, and manufacturing processes. Two proprietary capsids anchor the platform: ATC-187, which delivers a fully human BAG3 transgene to cardiac tissue at 5-10-fold lower doses than conventional AAV9 or AAVrh74 capsids with homogeneous distribution across heart cells, and ATC-134, a blood-brain barrier penetrant capsid demonstrating greater than 90% neuron transduction in non-human primates. Affinia has also developed a proprietary high-yield manufacturing process achieving harvest titers above 6e15 vg/L, supporting potential commercial supply at 50-250L scale.

Affinia is a privately held, venture-backed company with no commercial revenue. It has raised approximately $210 million across a $60 million Series A (2020), $110 million Series B (2021, co-led by EcoR1 Capital and Farallon Capital), and $40 million Series C (October 2025, led by New Enterprise Associates with Eli Lilly & Company participation). The business model is clinical-stage gene therapy development oriented toward one-time treatment revenue; the lead asset is investigational and supplied at no cost to trial participants. Investors on the board include Atlas Venture, NEA, F-Prime Capital, and others, and management includes multiple former AveXis executives involved in the development and launch of Zolgensma.

Affinia Therapeutics firmographics

Firmographics
Name
Affinia Therapeutics
Legal name
Affinia Therapeutics, Inc.
Website
https://affiniatx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Affinia Therapeutics is a clinical-stage biotech developing rationally designed AAV gene therapies for rare diseases, with lead program AFTX-201 in Phase 1/2 trials for BAG3-associated dilated cardiomyopathy and a broader platform spanning cardiac and CNS indications.
Ownership category
akta.pro rank

Affinia Therapeutics industry classification

Industry
Product category
Gene Therapy / AAV Therapeutics
NAICS
Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV gene therapy
  • Gene therapy development
  • Cardiac gene therapy
  • Biologics manufacturing
  • Rare disease therapeutics

Where Affinia Therapeutics is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Affinia Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Gene Therapy Development: Affinia Therapeutics is a clinical-stage biotech company developing gene therapies. No commercial revenue yet as the lead program AFTX-201 is in Phase 1/2 clinical trials. The company is funded through venture capital financing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Affinia Therapeutics product offering

Product offering

Core offering

Affinia Therapeutics develops rationally designed AAV gene therapies targeting rare and prevalent diseases of the heart and central nervous system, with lead candidate AFTX-201 delivering a fully human BAG3 transgene via the proprietary ATC-187 capsid for BAG3-associated dilated cardiomyopathy. The company's ART platform combines AI, structural modeling, and next-generation sequencing to engineer novel capsids, payloads, and manufacturing processes that achieve superior tissue targeting at 5-10-fold lower doses than conventional AAV gene therapies.

Product overview

Affinia Therapeutics is a clinical-stage biotech company developing a pipeline of first-in-class and best-in-class AAV gene therapies. The core offering includes AFTX-201, an investigational gene therapy for BAG3-associated dilated cardiomyopathy, which uses the proprietary ATC-187 capsid delivered via a one-time IV infusion. The company operates the ART (Affinia Rationally-designed Therapies) platform that employs AI and structural modeling to rationally design novel capsids (ATC-187 for cardiac, ATC-134 for CNS), payloads, and manufacturing processes. The platform enables lower dosing (5-10-fold) than conventional AAV gene therapies while achieving superior tissue transduction. Pipeline also includes programs for CNS diseases using BBB-penetrant capsids and collaborations for Myotonic Dystrophy Type 1.

Differentiator

Problem solved

Functional benefit

Products and services

  • AFTX-201 Investigational AAV gene therapy delivering a fully human, full-length BAG3 transgene via the proprietary ATC-187 capsid, designed to address the underlying genetic cause of BAG3-associated dilated cardiomyopathy. Engineered for efficient cardiac transduction at doses 5-10-fold lower than conventional AAV gene therapies, administered as a one-time IV infusion.

Quantifiable outcome

  • Doses 5-10-fold lower than conventional AAV gene therapies
  • +4 more outcomes

Companies that use Affinia Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Affinia Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Affinia Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor, core and strategic.

  • Houston Methodist HospitalminorOthers · 1 January 2026First planned clinical trial site for the UPBEAT clinical trial investigating AFTX-201 in BAG3 DCM patients.
  • Forge BiologicscoreStrategic or Co-development PartnerForge Biologics serves as the GMP manufacturing partner for AFTX-201 production. The manufacturing process was successfully developed by Affinia and transferred to Forge for clinical supply manufacturing.
  • Modalis TherapeuticsstrategicStrategic or Co-development PartnerJoint collaboration pairing Affinia's myotropic capsid ATC-187 with Modalis' epigenetic editing payload for development of a potential best-in-class gene therapy for Myotonic Dystrophy Type 1 (DM1).
  • Montréal Heart InstituteminorOthersCanadian research institution with Dr. Rafik Tadros involved as a key opinion leader in BAG3 DCM research.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Affinia Therapeutics competitors and assessment

Company assessment

Direct peers

  • Lexeo Therapeutics: Clinical-stage gene therapy company focused on cardiac diseases, including AAV-based therapies for genetic cardiomyopathies. Directly comparable as a cardiac-focused AAV gene therapy developer in similar stage and indication space as Affinia.
  • Rocket Pharmaceuticals: Clinical-stage gene therapy company developing AAV and lentiviral therapies for rare diseases, including cardiac and CNS indications. Comparable as a multi-platform rare disease gene therapy developer at similar clinical stage.
  • Tenaya Therapeutics: Genetic medicines company developing AAV gene therapies and other modalities for cardiomyopathies and heart failure. Directly comparable as a cardiac-focused genetic medicine developer with gene therapy programs.
  • Krystal Biotech: Commercial-stage gene therapy company with approved AAV-based therapy (VYJUVEK) for rare dermatological disease. Comparable as a clinical-to-commercial AAV gene therapy developer focused on rare monogenic diseases.
  • uniQure: Clinical-stage AAV gene therapy company developing treatments for hemophilia, Huntington's disease, and other rare diseases. Comparable as an established AAV gene therapy developer at similar clinical stage.
  • Taysha Gene Therapies: Clinical-stage gene therapy company developing AAV-based therapies for CNS and rare diseases, led by former AveXis CEO Sean Nolan (now Affinia's Chairman). Comparable leadership pedigree and AAV gene therapy focus.
  • Solid Biosciences: Clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other rare neuromuscular diseases. Comparable as an AAV gene therapy developer for rare genetic diseases.

Broad incumbents

  • REGENXBIO: Established AAV gene therapy platform company with approved therapy (ABECMA collab) and broad pipeline across ophthalmology, CNS, and metabolic diseases. Larger incumbent with comparable AAV platform technology and broader indication scope.
  • BioMarin Pharmaceutical: Large rare disease biotech that developed and launched Roctavian, an AAV5 gene therapy for hemophilia A. Comparable as an established player commercializing AAV gene therapy for rare genetic diseases.
  • Novartis (AveXis): Large pharmaceutical company that acquired AveXis for $8.7B and commercializes Zolgensma, the first systemic AAV gene therapy. Comparable as the established leader in AAV gene therapy commercialization and Affinia's lineage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Affinia Therapeutics social profiles

Digital presence

Affinia Therapeutics compliance and trust

Trust signal

Compliance4 records

Affinia Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Affinia Therapeutics leadership team

Management profile

Number of profiles

Profiles16 records

Affinia Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Affinia Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Affinia Therapeutics

What does Affinia Therapeutics do?

Affinia Therapeutics develops rationally designed AAV gene therapies targeting rare and prevalent diseases of the heart and central nervous system, with lead candidate AFTX-201 delivering a fully human BAG3 transgene via the proprietary ATC-187 capsid for BAG3-associated dilated cardiomyopathy. The company's ART platform combines AI, structural modeling, and next-generation sequencing to engineer novel capsids, payloads, and manufacturing processes that achieve superior tissue targeting at 5-10-fold lower doses than conventional AAV gene therapies.

Is Affinia Therapeutics a public or private company?

Affinia Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Affinia Therapeutics founded?

Affinia Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Affinia Therapeutics based?

Affinia Therapeutics is headquartered in Waltham, United States, in the North America region.

How does Affinia Therapeutics make money?

One revenue line is on record: gene Therapy Development.

Who are Affinia Therapeutics's main competitors?

Direct peers on record are Lexeo Therapeutics, Rocket Pharmaceuticals, Tenaya Therapeutics, Krystal Biotech, uniQure, Taysha Gene Therapies and Solid Biosciences. Broad incumbents are REGENXBIO, BioMarin Pharmaceutical and Novartis (AveXis).

Does Affinia Therapeutics have an API?

No public API is recorded for Affinia Therapeutics.

What industry is Affinia Therapeutics in?

Affinia Therapeutics's product category is Gene Therapy / AAV Therapeutics. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 5417.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageAffinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026Affinia Therapeutics will present AFTX-201 preclinical and Phase 1/2 UPBEAT trial data at the HFSA Annual Scientific Meeting 2026. The gene therapy targets BAG3-associated dilated cardiomyopathy, with preclinical studies showing restored cardiac function. The trial is open to U.S. and Canadian centers.Business Wire BlogAffinia Therapeutics’ AFTX-201 and UPBEAT™ Clinical Trial in BAG3 DCM Featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026Affinia Therapeutics will present AFTX-201 preclinical and UPBEAT trial data at the HFSA 2026 meeting. The gene therapy targets BAG3-associated DCM, with preclinical studies showing restored cardiac function. The company also sponsors an industry innovation event on October 11.YahooAffinia Therapeutics receives FDA orphan drug designation for AFTX-201Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, an investigational gene therapy delivered via single intravenous infusion for BAG3-associated dilated cardiomyopathy, a genetic condition causing progressive heart failure. The therapy is currently being evaluated in the Phase I/II UPBEAT clinical trial recruiting participants aged 18 to 55 in the US and Canada. The designation provides development incentives including tax credits, user fee exemptions, and potential market exclusivity if approved.Pharmaceutical TechnologyAffinia Therapeutics receives FDA orphan drug designation for AFTX-201Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, an investigational gene therapy for BAG3-associated dilated cardiomyopathy, a genetic condition causing progressive heart failure. The therapy uses a functional BAG3 transgene with the company's proprietary capsid for targeted heart delivery at lower doses, and is currently being studied in the Phase I/II UPBEAT clinical trial in the US and Canada. The orphan drug designation provides development incentives including tax credits, user fee exemptions, and potential market exclusivity upon approval.Business Wire BlogFDA Grants Orphan Drug Designation to Affinia Therapeutics’ AFTX-201 for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)The FDA granted Orphan Drug designation to Affinia Therapeutics' AFTX-201, an investigational gene therapy designed to address the underlying genetic mutation causing BAG3-associated dilated cardiomyopathy. AFTX-201 is being evaluated in the UPBEAT Phase 1/2 clinical trial currently recruiting patients at multiple sites in the U.S. and Canada. The designation provides development incentives including tax credits, user fee exemptions, and potential seven years of market exclusivity, addressing a condition with significant unmet medical need as there is currently no approved treatment targeting the underlying mechanism.BioSpaceFDA Grants Orphan Drug Designation to Affinia Therapeutics’ AFTX-201 for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM)The FDA granted orphan drug designation to Affinia Therapeutics' AFTX-201 for BAG3-associated dilated cardiomyopathy. The one-time IV gene therapy targets the underlying mutation, with preclinical data showing restored cardiac function. The UPBEAT Phase 1/2 trial is actively recruiting in the U.S. and Canada.Financial PostAffinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DAffinia Therapeutics announced that Health Canada approved its clinical trial application (CTA) for AFTX-201, an investigational gene therapy for BAG3-associated dilated cardiomyopathy, enabling the initiation of the UPBEAT Phase 1/2 clinical trial in Canada. The trial, already cleared by the FDA with Fast Track designation and granted Orphan Drug designation by the EMA, will evaluate the safety and preliminary efficacy of a single intravenous infusion of AFTX-201, which uses a proprietary capsid designed for efficient cardiac transduction at doses 5-10-fold lower than conventional gene therapies. BAG3 DCM is a serious inherited heart condition affecting more than 70,000 patients in Canada, the EU, the U.S., and the U.K., with no existing treatment targeting its underlying genetic mechanism.Pharmaceutical TechnologyAffinia receives fast track designation from FDA for AFTX-201Affinia Therapeutics has received FDA Fast Track Designation for AFTX-201, an investigational gene therapy for BAG3-associated dilated cardiomyopathy, currently being evaluated in the Phase I/II UPBEAT clinical trial. The designation aims to accelerate the development and review process for medicines addressing unmet medical needs in serious conditions, allowing for early FDA feedback and potential rolling submission of marketing applications. In October 2025, Affinia Therapeutics raised $40 million in a Series C funding round.Business Wire BlogAffinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)The FDA granted Fast Track designation to Affinia Therapeutics' AFTX-201, an investigational gene therapy for BAG3-associated dilated cardiomyopathy, which is being evaluated in the ongoing UPBEAT clinical trial. The therapy leverages a proprietary capsid engineered for efficient cardiac transduction at doses 5-10-fold lower than conventional AAV gene therapies, with preclinical studies demonstrating complete restoration of cardiac function in animal models. Fast Track designation enables more frequent FDA interactions and potential accelerated approval pathways, which could shorten the development timeline to approval for this rare genetic heart disease.